Skip to content
lifestyle.epubzone.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
July 20, 2026
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
July 6, 2026
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
June 29, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
June 26, 2026
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
June 25, 2026
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
May 13, 2026
←
Previous Page
1
2